2006
DOI: 10.1159/000092883
|View full text |Cite
|
Sign up to set email alerts
|

Promotility Medications – Now and in the Future

Abstract: Gastrointestinal promotility drugs stimulate smooth muscle contractions to enhance gastric emptying and small and large bowel transit. Currently available drug classes with prokinetic properties include antidopaminergic agents, serotonergic agents, and motilin-receptor agonists. Due to moderate prokinetic effects, poor symptomatic responses and the presence of adverse effects, there is a clear need for new classes of prokinetics. Several newer prokinetic drugs and drug classes are currently under evaluation. S… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
61
0
3

Year Published

2007
2007
2018
2018

Publication Types

Select...
3
3
2

Relationship

0
8

Authors

Journals

citations
Cited by 58 publications
(64 citation statements)
references
References 231 publications
0
61
0
3
Order By: Relevance
“…The Rome III working group defined functional dyspepsia as the presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic, or metabolic disease that is likely to explain them [Tack et al 2006]. Symptoms should be present for a minimum of 3 months; however, symptoms for greater than 6 months are typical.…”
Section: Functional Dyspepsiamentioning
confidence: 99%
See 1 more Smart Citation
“…The Rome III working group defined functional dyspepsia as the presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic, or metabolic disease that is likely to explain them [Tack et al 2006]. Symptoms should be present for a minimum of 3 months; however, symptoms for greater than 6 months are typical.…”
Section: Functional Dyspepsiamentioning
confidence: 99%
“…Dyspepsia is defined as having one or more symptoms of epigastric pain, burning, postprandial fullness, or early satiation [Tack et al 2006]. Bloating and nausea often coexist with dyspepsia but are nonspecific and are thus not included in its definition.…”
Section: Introductionmentioning
confidence: 99%
“…Serotonin gilt auch als wichtiger Neurotransmitter im enterischen Nervensystem. In der Humanmedizin existieren mittlerweile verschiedene Therapieansätze zur Behandlung gastrointestinaler Motilitätsstörungen bei denen Serotonin-Agonisten eine Schlüsselrolle spielen (Karamanolis und Tack 2006). Im equinen Darm scheinen bei der Regulation der Motorik vor allem 5-HT3-und 5-HT4-Rezeptoren eine Rolle zu spielen (Weiss et al 2002, Sasaki et al 2005.…”
Section: Kontrolle Durch Das Enterische Nervensystem (Ens) Und Durch unclassified
“…So hat der dopaminerge Antagonist Metoclopramid eine agonistische Wirkung auf 5-HT4-Rezeptoren und kann so lokal die gastrointestinale Motilität steigern (Abb. 2) (Karamanolis und Tack 2006). Die intestinale Motorik kann zum einen durch direkte Beeinflussung der glatten Muskulatur gesteuert werden, zum anderen sind auch die Neurone im myenterischen Plexus ein Angriffspunkt zur Modulation der Muskelaktionen.…”
Section: Kontrolle Durch Das Enterische Nervensystem (Ens) Und Durch unclassified
“…19 It also acts as a moderate agonist at the serotonergic 5-HT 4 receptor and to a lesser extent on 5-HT 3 receptors. 20,21 The serotonergic (5-HT 4 ) component of Levosulpiride may enhance its therapeutic efficacy in gastrointestinal disorders. 22 This property, together with antagonism at D2 receptors, may contribute to its gastrointestinal prokinetic effect.…”
Section: Introductionmentioning
confidence: 99%